Le Lézard
Classified in: Transportation, Health, Science and technology
Subject: PLW

BioArctic receives new patent in the US for blood-brain barrier transport technology

STOCKHOLM, Nov. 14, 2022 /PRNewswire/ --  BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) has granted BioArctic a new platform patent for a technology for transporting biopharmaceuticals across the blood-brain barrier. The patent, which is part of the company's Brain Transporter patent portfolio, will take effect on November 15, 2022, and expire in 2037.

The blood-brain barrier protects the brain from foreign substances by restricting the passage of these substances into the brain. The patented technology (US patent no. 11,498,974) has been developed to facilitate the transport of biopharmaceuticals across this barrier, thereby potentially improving drug efficacy. 

"We are pleased that the US Patent and Trademark Office has granted this new patent. Improved transportation of biopharmaceuticals across the blood-brain barrier may lead to improved efficacy and reduced side-effects in current and future treatments of brain disorders," says Gunilla Osswald, CEO, BioArctic. 

The information was released for public disclosure, through the agency of the contact persons below, on November 14, 2022, at 08:00 a.m. CET

For further information, please contact: 

Gunilla Osswald, CEO   
E-mail:  [email protected]                                  
Phone: +46 8 695 69 30                                                                     

Oskar Bosson, VP Communications and IR
E-mail:  [email protected] 
Phone: +46 70 410 71 80 

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and ALS. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic's Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

The following files are available for download:


BioArctic receives new patent in the US for blood-brain barrier transport technology


SOURCE BioArctic

These press releases may also interest you

at 20:54
MSC Euribia is the most energy-efficient cruise ship design ever - powered by LNG and featuring a range of technologies and solutions that minimize impact on the air and marine environmentTonight's traditional maritime ceremony will be attended by...

at 20:40
Researchers at Kanazawa University report in ACS Nano how ultrathin layers of tin disulfide can be used to accelerate the chemical reduction of carbon dioxide - a finding that is highly relevant for our quest towards a carbon-neutral society....

at 20:37
FLO Chief Product Officer Nathan Yang issued the following statement in response to the announcement that multiple automakers will adopt the North America Charging Standard (NACS):...

at 20:30
The "Supercapacitors: Technology Developments and Global Markets" report has been added to  ResearchAndMarkets.com's offering. The report covers the market for supercapacitors with regard to the end-user base across different regions. It also...

at 20:27
D2L Inc. ("D2L" or the "Company"), a global learning technology company, today announced that the nominees listed in its management information circular were elected as directors of the company at its Annual Meeting of Shareholders held on June 8,...

at 20:25
CIQ, the company building innovation with Rocky Linux, has added a new slate of assets to CIQ Mountain to address the needs of all HPC users. The Mountain repo as a service portfolio has been expanded to include full-stack high performance computing...

News published on and distributed by: